Overview

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Status:
Terminated

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

MEI Pharma, Inc.

Collaborator:

SCRI Development Innovations, LLC

Treatments:

Topotecan